Thomas Beetham

Thomas Beetham

Chief Operating OfficeratViridian Therapeutics, Inc.\DE· In proxies 2021–2025

Pay in FY2025+365% from the year before · Viridian Therapeutics, Inc.\DE stock +62.3% the same year

Thomas Beetham was paid $3.8M in FY2025 (Dec), up 365%. Viridian Therapeutics, Inc.\DE stock rose 62.3% that year.

Pay$100 in the stock at the end of FY20 → $189
Pay is from the Summary Compensation Table of each Viridian Therapeutics, Inc.\DE proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Viridian Therapeutics, Inc.\DEPublic company · 5 yr
    • Chief Operating Officer2021 – Present · 5 yrStock in role +38%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?